CN112402564A - Mongolian medicine composition gel and preparation method thereof - Google Patents
Mongolian medicine composition gel and preparation method thereof Download PDFInfo
- Publication number
- CN112402564A CN112402564A CN202011400061.9A CN202011400061A CN112402564A CN 112402564 A CN112402564 A CN 112402564A CN 202011400061 A CN202011400061 A CN 202011400061A CN 112402564 A CN112402564 A CN 112402564A
- Authority
- CN
- China
- Prior art keywords
- parts
- phase
- stirring
- cross
- medicinal powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
Abstract
The application relates to the field of medicines, and discloses a Mongolian medicine composition gel which comprises the following components in parts by weight: 5-7 parts of cross-linked framework sodium polyacrylate (P46NF), 1-2 parts of sodium polyacrylate (P55N), 0.1-0.2 part of cross-linking agent dihydroxyaluminum, 0.5-0.25 part of cross-linking regulator tartaric acid, 0.05-0.1 part of EDTA-2Na (disodium ethylene diamine tetraacetate), 3-5 parts of tackifier (N500), 20-40 parts of humectant glycerol, 1-5 parts of transdermal enhancer azone, 0.1-0.3 part of bacteriostatic agent (CMP), 0.5-1.0 part of stabilizer (EZ-1), 40-70 parts of deionized water and 10-20 parts of medicinal powder. Also discloses a preparation method of the gel. The gel has lasting drug effect and green and environment-friendly preparation process.
Description
Technical Field
The application relates to the field of medicines, in particular to a Mongolian medicine composition gel and a preparation method thereof.
Background
Transdermal drug delivery originates from China, and transdermal drug delivery preparations are receiving wide attention all over the world due to their unique advantages, and become hot spots of research in the pharmaceutical industry all over the world. According to the prediction of the world health organization, over 30 percent of medicaments are changed into transdermal administration preparations within 2-3 years. The traditional Chinese medicine is a treasure in China, and from the long history of overcoming diseases in China, the traditional Chinese medicine is proved to have extremely high scientificity and strong vitality, and the traditional Chinese medicine transdermal administration technology is a wonderful product in the treasury of the traditional Chinese medicine, keeps the characteristic advantages of the traditional Chinese medicine, and has practical and profound significance in modifying, innovating and developing traditional Chinese medicine pasting preparations by applying modern medical equipment and modern traditional Chinese medicine gel transdermal administration technology.
However, in the traditional dosage form, the base material of the adhesive plaster is generally made of rubber or high polymer chemical materials, and the materials are compounds extracted by alcohol, so that the adhesive plaster has great stimulation to the skin, and although some domestic enterprises and research institutes have researched and developed the dosage form at present, most of the adhesive plaster adopts hot melt adhesive, the melting point of the hot melt adhesive is above 135 ℃, the adhesive plaster is only improved and processed, and the problem is not solved fundamentally. In addition, the common adhesive plaster patch has the matrix with the thickness of about 0.1 mm after being added with medicine and low medicine content, the ratio of the matrix to the medicine of the transdermal patch is about 9:1,
the three-minister pill consists of tabasheer, safflower and bezoar, is called as a three-component minister formula or a traditional Mongolian medicine formula with a picture of Mueller-3, has the functions of clearing heat, detoxifying, relieving cough, reducing sputum, relieving asthma, relieving convulsion and the like, and is mainly used for treating diseases such as lung heat, liver heat, palpitation and the like of children. At present, the two dosage forms of powder and watered pill are inconvenient for children to take and have poor compliance so as to influence the curative effect. The three ministerial pills loaded by ministerial standards are red water pills coated with vermilion, and the vermilion has certain side effects on infants. Therefore, the research on the improvement of the dosage form of the three-minister pill is urgent. The three-minister antipyretic patch for children is obtained by improving the dosage form of the three-minister traditional Mongolian medicine pill.
Disclosure of Invention
Aiming at the defects in the prior art, the invention improves the dosage form of the traditional Mongolian medicine three-minister pill and aims to provide a Mongolian medicine composition gel and a preparation method thereof.
In order to realize the purpose, the Mongolian medicine composition gel and the preparation method thereof adopt the following technical scheme:
the Mongolian medicine composition gel comprises the following components in parts by weight: 5-7 parts of cross-linked framework sodium polyacrylate (P46NF), 1-2 parts of sodium polyacrylate (P55N), 0.1-0.2 part of cross-linking agent dihydroxyaluminum, 0.5-0.25 part of cross-linking regulator tartaric acid, 0.05-0.1 part of EDTA-2Na, 3-5 parts of tackifier (N500), 20-40 parts of humectant glycerin, 1-5 parts of transdermal enhancer azone, 0.1-0.3 part of bacteriostatic agent (CMP), 0.5-1.0 part of stabilizer (EZ-1), 40-70 parts of deionized water and 10-20 parts of medicinal powder.
The medicinal powder comprises safflower, artificial bezoar and tabasheer, and preferably, the weight ratio of the safflower to the artificial bezoar to the tabasheer in the medicinal powder is 1:1: 1.
The invention also provides a preparation method of the Mongolian medicine composition gel, which comprises the following steps:
step one, preparing medicinal powder:
1) pulverizing Carthami flos into 40 mesh, adding 15 times of 60% ethanol as solvent, and reflux-extracting for 60-90min for 3 times to obtain Carthami flos extractive solution;
2) filtering the safflower extract through a 200-mesh sieve, concentrating under negative pressure to recover ethanol, concentrating to obtain an extract with the density of 1.2-1.3, or freeze-drying to obtain dry powder;
3) crushing artificial bezoar and tabasheer into 120-200-mesh medicinal powder;
adding glycerol into a stirrer, then adding cross-linked skeleton sodium polyacrylate (P46NF), sodium polyacrylate (P55N), cross-linking agent dihydroxyaluminum, EDTA-2Na, artificial bezoar and tabasheer powder, starting stirring for 10-20 minutes until a uniform paste semifluid is formed, and powder particles which are not visible to naked eyes are used as a phase A;
step three, preparing transdermal enhancer azone and stabilizer (EZ-1) in a container, and stirring until the mixture is completely uniform to be used as a phase B;
step four, adding deionized water into another container, completely dissolving tartaric acid, then adding bacteriostatic agent (CTM), adding tackifier (N500) under stirring, uniformly pulping, adding safflower extract after the tackifier is completely dissolved, and continuously stirring until the medicinal powder is uniformly dispersed to serve as a C phase; adding the phase B into the stirred phase C, and continuously stirring for 3-5 minutes;
step five, adding the beaten phase A into the mixture of the phase B and the phase C in the step four;
step six, turning on the vacuum of the stirrer until the pressure gauge is below 0.08Pa, and then stirring for 5-8 minutes until a viscous colloid is formed;
stopping stirring, vacuumizing, and starting a stirrer to discharge to a special coating machine hopper;
step eight, discharging materials by a hopper, starting the coating and slitting integrated machine, and setting the coating speed of the machine and the conveying speed of a conveying belt according to the yield requirement;
and step nine, curing for 8-12 hours and then packaging.
And after the phase C is contacted with the phase A in the step five, discharging to a hopper in the step seven, wherein the time is not too long, and preferably not more than half an hour.
Preferably, the coating time per batch is controlled within 20 minutes, and the longer time can cause difficulty in tail coating.
In the present application, the cross-linked backbone sodium polyacrylate is preferably NOVETAC P46N, and the sodium polyacrylate is preferably NO VETAC P55N, both of which are commercially available.
The remaining components in the present application, as will be appreciated by those skilled in the art, may be selected from those commonly used in the art. For example, the tackifier may be polyvinylpyrrolidone, the bacteriostatic agent may be benzalkonium chloride, and the stabilizer may be sodium hexametaphosphate.
In this application, sodium polyacrylate under aluminium ion's effect, the cross-linking forms three-dimensional water-retaining glue film, through special coating equipment coating in the non-woven fabrics with from the type rete, the solidification becomes to have elasticity hydrogel layer, through softening the stratum corneum and continuously promoting active ingredient and get into the human body behind the gel layer contact skin.
Compared with the prior art, the Mongolian medicine composition gel has the following beneficial effects:
(1) the water-soluble polymer material is used as a main component, so that the defects caused by rubber and a high polymer chemical material matrix are avoided, the medicine is always in an active state, the skin permeation of the active ingredient of the medicine is improved, the medicine can quickly reach a focus and has an obvious effect on the controlled slow release of the medicine, the medicine can uniformly release the medicine effect within 24 to 120 hours or more, the peak valley phenomenon of the medicine is avoided, the effective utilization rate of the medicine ingredient can be improved, and the long-acting constancy is realized. The local penetration plays the drug effect, the concentration of drug molecules in blood is low, and the toxic and side effects of the whole body caused by large drug absorption amount can not be generated.
(2) The gel is a neutral formula, the pH value of the gel is about 7, and traditional Chinese medicines and western medicines can be added; water-soluble, water-insoluble; various drugs such as acid drugs, alkaline drugs and the like have better affinity, and have no modification or influence on the drugs, so the compound is an ideal medical carrier added with various therapeutic drugs;
(3) the gel is different from general adhesive plaster and traditional black plaster after being prepared into a medicinal patch, the adhesive plaster has overlarge adhesion force to skin, can cause body hair to be damaged and is difficult to peel off, so that the pain of a patient is caused, the black plaster is disposable and must be heated when being used, the body hair is adhered and the skin is polluted, and the gel can moderate the adhesion force to the human body, is easy to peel off, can not tear the adhesive hair and can be repeatedly torn off and pasted due to adjustable viscosity and affinity.
(4) The gel contains the moisture content (50-60 percent) corresponding to the skin surface, has high moisture content and strong water locking property, keeps the basically unchanged moisture content after being continuously pasted for 24 hours, keeps the water environment similar to the epidermis, enhances the affinity to the skin of a human body and creates the optimal condition for the transdermal absorption of the medicament. The medicine components are induced by the temperature of the human body to permeate into the human body, the efficacy of the medicine can be adjusted by the temperature of the skin, the medicine can stop volatilizing after being taken off, the administration dosage is controllable, and the medicine is seriously volatilized after the common patch is taken off so as to be easily lost in a short time.
(5) The gel agent is prepared by synthesizing a high-molecular hydrophilic material, particularly, the temperature is controlled below 75 ℃ in the matrix preparation process, and the volatilization and damage of active ingredients of the medicine cannot be caused in the processing process;
(6) this dosage form of this application gel is owing to adopt the green material of hydrophilicity, and the diluent adopts medicine level purified water, and the transdermal agent adopts waterborne natural material, and the matrix can be taken orally completely, does not have naked light processing, selects for use medicine level to prepare the membrane and prepares cloth (large mesh dacron non-woven fabrics) and contain the processing coating of cotton 75% above water thorn cloth, does not have environmental pollution, accords with the production requirement of national patch completely.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
Example 1
The Mongolian medicine composition gel comprises the following components in parts by weight: 6 parts of cross-linked framework sodium polyacrylate (the embodiment selects market NOVETAC P46N), 1 part of sodium polyacrylate (the embodiment selects market NOVETAC P55N), 0.16 part of cross-linking agent dihydroxyaluminum, 0.25 part of cross-linking regulator tartaric acid, 0.1 part of EDTA-2NA (ethylene diamine tetraacetic acid disodium), 4 parts of tackifier (the embodiment selects market NOVEPHIL500), 20 parts of humectant glycerol, 3 parts of transdermal enhancer azone, 0.2 part of bacteriostatic agent (CMP), 1 part of stabilizer (EZ-1), 54.29 parts of deionized water and 10 parts of medicinal powder.
The medicinal powder comprises safflower, artificial bezoar and tabasheer, and the weight ratio of the safflower to the artificial bezoar to the tabasheer in the medicinal powder is 1:1: 1.
The preparation method of the Mongolian medicine composition gel comprises the following steps:
step one, preparing medicinal powder:
1) pulverizing Carthami flos into 40 mesh, adding 15 times of 60% ethanol as solvent, and reflux-extracting for 60min for 3 times each time to obtain Carthami flos extract;
2) filtering the extracting solution through a 200-mesh sieve, concentrating under negative pressure to recover ethanol, concentrating to obtain an extract with the density of 1.2-1.3, or freeze-drying to obtain dry powder;
3) crushing artificial bezoar and tabasheer into 120-200-mesh medicinal powder;
adding 2000g of glycerol into the egg beater, then adding 333.3g of NOVETAC P46N600g, NOVETAC P55N 100g, 16g of dihydroxyaluminum glycinate, 10g of EDTA-2Na, artificial bezoar and tabasheer powder respectively, starting stirring (middle grade), and stirring for 10-20 minutes until a uniform pasty semifluid is formed, and powder particles which are not visible to naked eyes are used as an A (glycerol phase) phase;
step three, preparing 300g of azone and 100g of stabilizer (EZ-1) in a measuring cup, and stirring until the mixture is completely uniform to be used as a phase B;
step four, adding 5429g of deionized water into another container, completely dissolving 25g of tartaric acid, then adding 20g of bacteriostatic agent (CMP), adding 400g of tackifier (N500) under high-speed stirring, uniformly pulping, adding 333.3g of safflower extract after the tackifier is completely dissolved (generally, continuously stirring for 15-20 minutes), and continuously stirring at high speed until the medicinal powder is uniformly dispersed to serve as a C phase (water phase); adding the phase B into the stirred phase C, and continuously stirring at a high speed for 3-5 minutes;
step five, adding the beaten phase A into the mixture of the phase B and the phase C in the step four;
step six, turning on the vacuum of the stirrer until the pressure gauge is below 0.08Pa, and then turning on the rapid stirring for 5-8 minutes until a viscous colloid is formed;
stopping stirring, vacuumizing, and starting a stirrer to discharge to a special coating machine hopper;
step eight, discharging materials by a hopper, starting the coating and slitting integrated machine, and setting the coating speed of the machine and the conveying speed of a conveying belt according to the yield requirement; the coating time of each batch is controlled within 20 minutes, and the excessive time can cause difficult tailing coating;
and step nine, curing for 8-12 hours and then packaging.
And after the phase C is contacted with the phase A in the step five, discharging to a hopper in the step seven, wherein the time is not too long, and preferably not more than half an hour.
In this embodiment, benzalkonium chloride may be used as the bacteriostatic agent, and sodium hexametaphosphate may be used as the stabilizer.
The test result of the gel paste proves that the gel paste is added with traditional Chinese medicines (extractum, medicinal mud and dry medicinal powder), the thickness of the paste is 1-1.3 mm, and the area is 6.5 multiplied by 9.0cm2Or 7.0X 10.0cm2About 3 grams, then; 2.5-3 g of ointment; the dry powder is about 1 g. The ratio of the matrix to the medicine is 6.5:3.5, and the unit administration and the lasting effect can be completely met.
Example 2
The Mongolian medicine composition gel comprises the following components in parts by weight: sodium polyacrylate NOVETAC P46N5 with cross-linked skeleton, sodium polyacrylate NOVETAC P55N 2, cross-linking agent dihydroxyaluminum 0.1, cross-linking regulator tartaric acid 0.5, EDTA-2NA 0.05, tackifier N500 0.1, stabilizer EZ-1 0.5, deionized water 40 and medicine powder 14.05.
The medicinal powder comprises safflower, artificial bezoar and tabasheer, and the weight ratio of the safflower to the artificial bezoar to the tabasheer in the medicinal powder is 1:1: 1.
The preparation method of the Mongolian medicine composition gel comprises the following steps:
step one, preparing medicinal powder:
1) pulverizing Carthami flos into 40 mesh, adding 15 times of 60% ethanol as solvent, and reflux-extracting for 60min for 3 times each time to obtain Carthami flos extract;
2) filtering the extracting solution through a 200-mesh sieve, concentrating under negative pressure to recover ethanol, concentrating to obtain an extract with the density of 1.2-1.3, or freeze-drying to obtain dry powder;
3) crushing artificial bezoar and tabasheer into 120-200-mesh medicinal powder;
secondly, adding 3200g of glycerol, then adding 468.3g of NOVETAC P46N500g, NO VETAC P55N 200g, 10g of dihydroxyaluminum glycinate, 5g of EDTA-2Na, artificial bezoar and tabasheer powder into a stirrer, starting stirring (middle grade), and stirring for 10-20 minutes until a uniform pasty semifluid is formed and NO macroscopic powder particles are formed as a (glycerol phase) phase A;
step three, preparing 100g of azone and 50g of stabilizer (EZ-1) in a measuring cup, and stirring until the mixture is completely uniform to be used as a phase B;
step four, after 4000g of deionized water is added into another container, 50g of tartaric acid is completely dissolved, then 30g of bacteriostatic agent (CMP) is added, 450g of tackifier (N500) is added under high-speed stirring, the mixture is uniformly pulped, 468.3g of safflower extract is added after the tackifier is completely dissolved (generally, continuous stirring is needed for 15-20 minutes), and the mixture is continuously stirred at high speed until the medicinal powder is uniformly dispersed to be used as a C phase (water phase); adding the phase B into the stirred phase C, and continuously stirring at a high speed for 3-5 minutes;
step five, adding the beaten phase A into the mixture of the phase B and the phase C in the step four;
step six, turning on the vacuum of the stirrer until the pressure gauge is below 0.08Pa, and then turning on the rapid stirring for 5-8 minutes until a viscous colloid is formed;
stopping stirring, vacuumizing, and starting a stirrer to discharge to a special coating machine hopper;
step eight, discharging materials by a hopper, starting the coating and slitting integrated machine, and setting the coating speed of the machine and the conveying speed of a conveying belt according to the yield requirement; the coating time of each batch is controlled within 20 minutes, and the excessive time can cause difficult tailing coating;
and step nine, curing for 8-12 hours and then packaging.
And after the phase C is contacted with the phase A in the step five, discharging to a hopper in the step seven, wherein the time is not too long, and preferably not more than half an hour.
In this embodiment, the tackifier may be polyvinylpyrrolidone, the bacteriostatic agent may be benzalkonium chloride, and the stabilizer may be sodium hexametaphosphate, for example.
The test result of the gel paste proves that the gel paste is added with traditional Chinese medicines (extractum, medicinal mud and dry medicinal powder), the thickness of the paste is 1-1.3 mm, and the area is 5.0 multiplied by 12.0cm2Or 7.0X 10.0cm2About 12 grams, time; 10-12 g of ointment; the dry powder is about 1.0-1.2 g. The ratio of the matrix to the medicine is 9:1, and the unit administration and the lasting effect can be completely met.
Example 3
The Mongolian medicine composition gel comprises the following components in parts by weight: 6.5 parts of cross-linked framework sodium polyacrylate NOVETAC P46N 6.5, 55N 1.5.5 parts of sodium polyacrylate NOVETAC P55, 0.2 part of cross-linking agent dihydroxyaluminum, 0.32 part of cross-linking regulator tartaric acid, 0.07 part of EDTA-2Na (ethylene diamine tetraacetic acid disodium), 3 parts of tackifier (N500), 40 parts of humectant glycerol, 5 parts of transdermal enhancer azone, 0.1 part of bacteriostatic agent (CMP), 10.8 parts of stabilizer EZ-10, 70 parts of deionized water and 20 parts of medicinal powder.
The medicinal powder comprises safflower, artificial bezoar and tabasheer, and the weight ratio of the safflower to the artificial bezoar to the tabasheer in the medicinal powder is 1:1: 1.
The preparation method of the Mongolian medicine composition gel comprises the following steps:
step one, preparing medicinal powder:
1) pulverizing Carthami flos into 40 mesh, adding 15 times of 60% ethanol as solvent, and reflux-extracting for 60min for 3 times each time to obtain Carthami flos extract;
2) filtering the extracting solution through a 200-mesh sieve, concentrating under negative pressure to recover ethanol, concentrating to obtain an extract with the density of 1.2-1.3, or freeze-drying to obtain dry powder;
3) crushing artificial bezoar and tabasheer into 120-200-mesh medicinal powder;
step two, adding 4000g of glycerol into a stirrer, then adding 666.6g of NOVETAC P46N650g, NO VETAC P55N 150g, 20g of dihydroxyaluminum glycinate, 7g of EDTA-2Na, artificial bezoar and tabasheer powder respectively, starting stirring (middle grade), and stirring for 10-20 minutes until a uniform pasty semifluid is formed, and powder particles which are not visible to naked eyes are used as a (glycerol phase) phase A;
step three, preparing 500g of azone and 80g of stabilizer (EZ-1) in a measuring cup, and stirring until the mixture is completely uniform to be used as a phase B;
step four, adding 7000g of deionized water into another container, completely dissolving 32g of tartaric acid, then adding 10g of bacteriostatic agent, adding 300g of tackifier under high-speed stirring, pulping uniformly, adding 666.6g of safflower extract after the tackifier is completely dissolved (generally, continuously stirring for 15-20 minutes), and continuously stirring at high speed until the medicinal powder is uniformly dispersed to serve as a C phase (water phase); adding the phase B into the stirred phase C, and continuously stirring at a high speed for 3-5 minutes;
step five, adding the beaten phase A into the mixture of the phase B and the phase C in the step four;
step six, turning on the vacuum of the stirrer until the pressure gauge is below 0.08Pa, and then turning on the rapid stirring for 5-8 minutes until a viscous colloid is formed;
stopping stirring, vacuumizing, and starting a stirrer to discharge to a special coating machine hopper;
step eight, discharging materials by a hopper, starting the coating and slitting integrated machine, and setting the coating speed of the machine and the conveying speed of a conveying belt according to the yield requirement; the coating time of each batch is controlled within 20 minutes, and the excessive time can cause difficult tailing coating;
and step nine, curing for 8-12 hours and then packaging.
And after the phase C is contacted with the phase A in the step five, discharging to a hopper in the step seven, wherein the time is not too long, and preferably not more than half an hour.
In this embodiment, the tackifier may be polyvinylpyrrolidone, the bacteriostatic agent may be benzalkonium chloride, and the stabilizer may be sodium hexametaphosphate, for example.
The test result of the gel paste proves that the gel paste is added with traditional Chinese medicines (extractum, medicinal mud and dry medicinal powder), the thickness of the paste is 1-1.3 mm, and the area is 5 multiplied by 12.0cm2Or 7.0X 10.0cm2About 12 grams, time; 10-12 g of ointment; the dry powder is about 1.0-1.2 g. The ratio of the matrix to the medicine is 9:1, and the unit administration and the lasting effect can be completely met.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.
Claims (5)
1. The Mongolian medicine composition gel is characterized by comprising the following components in parts by weight: 5-7 parts of cross-linked framework sodium polyacrylate (P46NF), 1-2 parts of sodium polyacrylate (P55N), 0.1-0.2 part of cross-linking agent dihydroxyaluminum, 0.5-0.25 part of cross-linking regulator tartaric acid, 0.05-0.1 part of EDTA-2Na, 3-5 parts of tackifier (N500), 20-40 parts of humectant glycerin, 1-5 parts of transdermal enhancer azone, 0.1-0.3 part of bacteriostatic agent (CMP), 0.5-1.0 part of stabilizer (EZ-1), 40-70 parts of deionized water and 10-20 parts of medicinal powder.
2. The mongolian medicine composition gel according to claim 1, characterized in that said medicinal powder comprises safflower, artificial bezoar and tabasheer, and the weight ratio of safflower, artificial bezoar and tabasheer in said medicinal powder is 1:1: 1.
3. A preparation method of the Mongolian medicine composition gel is characterized by comprising the following steps:
step one, preparing medicinal powder:
1) pulverizing Carthami flos into 40 mesh, adding 15 times of 60% ethanol as solvent, and reflux-extracting for 60-90min for 3 times to obtain Carthami flos extractive solution;
2) filtering the safflower extract through a 200-mesh sieve, concentrating under negative pressure to recover ethanol, concentrating to obtain an extract with the density of 1.2-1.3, or freeze-drying to obtain dry powder;
3) crushing artificial bezoar and tabasheer into 120-200-mesh medicinal powder;
adding glycerol into a stirrer, then adding cross-linked skeleton sodium polyacrylate (P46NF), sodium polyacrylate (P55N), cross-linking agent dihydroxyaluminum, EDTA-2Na, artificial bezoar and tabasheer powder, starting stirring for 10-20 minutes until a uniform paste semifluid is formed, and powder particles which are not visible to naked eyes are used as a phase A;
step three, preparing transdermal enhancer azone and stabilizer in a container, and stirring until the mixture is completely uniform to be used as a phase B;
step four, after adding deionized water into another container, completely dissolving tartaric acid, then adding bacteriostatic agent, adding tackifier (N500) under the condition of stirring, uniformly pulping, adding safflower extract after the tackifier is completely dissolved, and continuously stirring until the medicinal powder is uniformly dispersed to be used as phase C; adding the phase B into the stirred phase C, and continuously stirring for 3-5 minutes;
step five, adding the beaten phase A into the mixture of the phase B and the phase C in the step four;
step six, turning on the vacuum of the stirrer until the pressure gauge is below 0.08Pa, and then stirring for 5-8 minutes until a viscous colloid is formed;
stopping stirring, vacuumizing, and starting a stirrer to discharge to a special coating machine hopper;
step eight, discharging materials by a hopper, starting the coating and slitting integrated machine, and setting the coating speed of the machine and the conveying speed of a conveying belt according to the yield requirement;
and step nine, curing for 8-12 hours and then packaging.
4. The method for preparing the gel of the Mongolian medicine composition as claimed in claim 3, wherein the C phase is contacted with the A phase in the fifth step, and then the C phase is discharged to a hopper for no more than half an hour.
5. The method of claim 3, wherein the time for coating each batch is controlled to be less than 20 minutes, which may lead to difficulties in coating the tailings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011400061.9A CN112402564A (en) | 2020-12-03 | 2020-12-03 | Mongolian medicine composition gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011400061.9A CN112402564A (en) | 2020-12-03 | 2020-12-03 | Mongolian medicine composition gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112402564A true CN112402564A (en) | 2021-02-26 |
Family
ID=74830001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011400061.9A Pending CN112402564A (en) | 2020-12-03 | 2020-12-03 | Mongolian medicine composition gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112402564A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343397A (en) * | 2014-08-25 | 2016-02-24 | 康美药业股份有限公司 | Areca nut cataplasm, preparation method and application thereof |
| CN109091290A (en) * | 2018-08-08 | 2018-12-28 | 中国科学院长春应用化学研究所 | It is a kind of persistently effectively defervescence plaster used and preparation method thereof |
| CN110585362A (en) * | 2019-10-22 | 2019-12-20 | 包金花 | Mongolian medicine composition and application thereof |
| CN110755410A (en) * | 2019-11-29 | 2020-02-07 | 四川省骨科医院 | Chinese medicine gel plaster and its matrix |
-
2020
- 2020-12-03 CN CN202011400061.9A patent/CN112402564A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343397A (en) * | 2014-08-25 | 2016-02-24 | 康美药业股份有限公司 | Areca nut cataplasm, preparation method and application thereof |
| CN109091290A (en) * | 2018-08-08 | 2018-12-28 | 中国科学院长春应用化学研究所 | It is a kind of persistently effectively defervescence plaster used and preparation method thereof |
| CN110585362A (en) * | 2019-10-22 | 2019-12-20 | 包金花 | Mongolian medicine composition and application thereof |
| CN110755410A (en) * | 2019-11-29 | 2020-02-07 | 四川省骨科医院 | Chinese medicine gel plaster and its matrix |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI231214B (en) | Pharmaceutical hydrogel compositions, drug delivery devices and methods | |
| JPS62178513A (en) | Sheet path in oral cavity | |
| CN1703250A (en) | Plaster | |
| US20020172712A1 (en) | Antiemetic, anti-motion sustained release drug delivery system | |
| CN112022919A (en) | Percutaneous-absorption artemisia vulgaris oil carrier gel and preparation method thereof | |
| CN101455654B (en) | Arginine ibuprofen gel and preparation method thereof | |
| CN110302144A (en) | A kind of slow-release type double-layered stomatocace film and preparation method thereof | |
| CN101703751B (en) | Emplastrum for treating white-plus disease and preparation method thereof | |
| KR20000062348A (en) | Extremely flexible plaster acting dermally or transdermally, and method for producing same | |
| CN112402564A (en) | Mongolian medicine composition gel and preparation method thereof | |
| CN110812420B (en) | Traditional Chinese medicine composition for treating oral ulcer, traditional Chinese medicine film agent, preparation method and application | |
| CN101274118B (en) | Physiotherapy electrode plate clamping self-pasting medicine carrying membrane and manufacture method thereof | |
| CN106344926A (en) | Post-crosslinked gel plaster substrate and method for preparing medicated plaster | |
| CN110680879A (en) | Traditional Chinese medicine film spraying agent for promoting blood circulation, stopping bleeding, removing necrotic tissue and promoting granulation and preparation method thereof | |
| CN110090198A (en) | A kind of slow-release canker sore gel and preparation method thereof with bioadhesive | |
| CN1552308A (en) | Nano spectrum endermatic medicinal paste and its preparation | |
| CN112546101A (en) | Traditional Chinese medicine compound for relieving eczema, sustained-release agent, preparation method and application | |
| CN1269206A (en) | Making process of Babu plaster for rheumatism and ostealiga | |
| CN113274444A (en) | Plaster for treating bronchial asthma and preparation method thereof | |
| CN101683376A (en) | Patch for treating toothache and method for producing the same | |
| CN105663029A (en) | Bioadhesion slow-release gel preparation for oral administration and preparation method thereof | |
| CN110893204A (en) | Clove compound hydrogel and preparation method thereof | |
| CN100374122C (en) | Calf serum deprotein oral cavity ointment and its preparation method | |
| CN116602942A (en) | Flurbiprofen gel emplastrum and preparation method thereof | |
| CN113262210B (en) | Traditional Chinese medicine plaster for treating hyperplasia of mammary glands and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210226 |
|
| RJ01 | Rejection of invention patent application after publication |